TriangleNCT04401579 · OUTCOME
Time to Recovery by Ethnicity
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Days
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Day 1 through Day 29
What was measured
Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care.
Analysis population: The intent-to-treat (ITT) population includes all participants who were randomized and for whom ethnicity was reported
Groups in this outcome
Remdesivir Plus Baricitinib
200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.
Remdesivir Plus Placebo
200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.
| Group | Source count |
|---|---|
| Remdesivir Plus Baricitinib | 509 |
| Remdesivir Plus Placebo | 508 |
Reported measurements
Not Hispanic or Latino
| Group | Source count |
|---|---|
| Remdesivir Plus Baricitinib | 246 |
| Remdesivir Plus Placebo | 240 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Remdesivir Plus Baricitinib | 7.0 | Not reported | 6.0 | 8.0 | Not reported |
| Remdesivir Plus Placebo | 9.0 | Not reported | 7.0 | 10.0 | Not reported |
Hispanic or Latino
| Group | Source count |
|---|---|
| Remdesivir Plus Baricitinib | 263 |
| Remdesivir Plus Placebo | 268 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Remdesivir Plus Baricitinib | 7.0 | Not reported | 6.0 | 8.0 | Not reported |
| Remdesivir Plus Placebo | 7.0 | Not reported | 6.0 | 9.0 | Not reported |
Source statistical analyses
- ci Lower Limit
- 1.08
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.60
- group Description
- This analysis is for Not Hispanic or Latino participants
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY
- param Type
- Cox Proportional Hazard
- param Value
- 1.31
- ci Lower Limit
- 0.89
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.31
- group Description
- This analysis is for Hispanic or Latino participants.
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY
- param Type
- Cox Proportional Hazard
- param Value
- 1.08
Complete source fields
- analyses
- ci Lower Limit
- 1.08
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.60
- group Description
- This analysis is for Not Hispanic or Latino participants
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY
- param Type
- Cox Proportional Hazard
- param Value
- 1.31
- ci Lower Limit
- 0.89
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.31
- group Description
- This analysis is for Hispanic or Latino participants.
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY
- param Type
- Cox Proportional Hazard
- param Value
- 1.08
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 6.0
- upper Limit
- 8.0
- value
- 7.0
- group Id
- OG001
- lower Limit
- 7.0
- upper Limit
- 10.0
- value
- 9.0
- denoms
- counts
- group Id
- OG000
- value
- 246
- group Id
- OG001
- value
- 240
- units
- Participants
- title
- Not Hispanic or Latino
- categories
- measurements
- group Id
- OG000
- lower Limit
- 6.0
- upper Limit
- 8.0
- value
- 7.0
- group Id
- OG001
- lower Limit
- 6.0
- upper Limit
- 9.0
- value
- 7.0
- denoms
- counts
- group Id
- OG000
- value
- 263
- group Id
- OG001
- value
- 268
- units
- Participants
- title
- Hispanic or Latino
- denoms
- counts
- group Id
- OG000
- value
- 509
- group Id
- OG001
- value
- 508
- units
- Participants
- description
- Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- 200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.
- id
- OG000
- title
- Remdesivir Plus Baricitinib
- description
- 200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.
- id
- OG001
- title
- Remdesivir Plus Placebo
- param Type
- MEDIAN
- population Description
- The intent-to-treat (ITT) population includes all participants who were randomized and for whom ethnicity was reported
- reporting Status
- POSTED
- time Frame
- Day 1 through Day 29
- title
- Time to Recovery by Ethnicity
- type
- PRIMARY
- unit Of Measure
- Days
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice